Search Results
Your search for The A matches 32997 pages
Showing 21351 - 21400Link Between Previous Treatment for Depression and Increased Risk of Receiving Nonguideline Treatment in Early-Stage Breast Cancer
Women with early-stage breast cancer previously treated for depression were more likely to receive nonguideline treatment for breast cancer, “probably contributing to poorer overall and cancer-specific survival,” according to a nationwide Danish cohort study reported in the Journal of...
Postinduction Minimal Residual Disease Predicts Outcome and Benefit From ASCT in NPM1-Mutant AML
In an analysis of a French trial reported in the Journal of Clinical Oncology, Balsat et al found that postinduction minimal residual disease was predictive of outcome and benefit from allogeneic stem cell transplantation (ASCT) in patients with NPM1-mutant acute myeloid leukemia (AML). The study...
Gleevec Is Saving My Life but at a Cost
Like many patients in the chronic phase of chronic myeloid leukemia (CML), my cancer was discovered during a routine physical, when an off-the-chart white blood cell count signaled a serious problem that my primary care physician attributed to unspecified internal bleeding. Fortunately for me, my...
Nivolumab in Recurrent Advanced Urothelial Carcinoma
In the phase I/II CheckMate 032 trial reported in The Lancet Oncology, Padmanee Sharma, MD, of The University of Texas MD Anderson Cancer Center, and colleagues found that nivolumab (Opdivo) was active in locally advanced or metastatic urothelial carcinoma progressing after platinum-based therapy....
Long-Term Effects of Finasteride in Patients From the Prostate Cancer Prevention Trial
In the Prostate Cancer Prevention Trial finasteride was found to reduce the risk of low-grade prostate cancer but to have no effect on overall survival. Results of the trial, in which 18,880 men were randomized to receive finasteride or placebo for 7 years, were reported in 2003. In a recent study...
Genetic Markers Associated With Pathologic Complete Response Identified in HER2-Positive Breast Cancer
In an analysis reported in JAMA Oncology, Fumagalli et al identified genetic markers associated with pathologic complete response among women with early-stage HER2-positive breast cancer receiving neoadjuvant therapy in the phase III NeoALTTO trial. Christos Sotiriou, MD, PhD, of Institut Jules...
Primary Care Physician Involvement in Decision-Making in Breast Cancer
Most women with breast cancer reported high primary care physician quality, engagement, and communication, with a minority reporting high levels of primary care physician participation in treatment decisions, according to a study reported by Lauren P. Wallner, PhD, MPH, of the University of...
SU2C Launches $7.5 Million Initiative in Research Grants Focusing on Immuno-oncology
Stand Up To Cancer (SU2C) is making $7.5 million in research grants available to early-career scientists who are pursuing innovative cancer research projects focusing on immuno-oncology, the American Association for Cancer Research recently announced. Funded by a grant from SU2C Visionary...
Adrian Lee, PhD, Named Director of the Institute for Precision Medicine at Pitt
Breast cancer researcher Adrian Lee, PhD, has been named Director of the Institute for Precision Medicine (IPM), a joint effort by the University of Pittsburgh Medical Center (UPMC) and the University of Pittsburgh to move biomedical research into personalized well-being and clinical care. Dr....
Baylor Welcomes New McNair Scholar, Bing Zhang, PhD
Bing Zhang, PhD, a computational biologist with a focus on cancer bioinformatics, has been named the newest McNair Scholar at Baylor College of Medicine. The McNair Scholar program at Baylor identifies influential researchers in breast and pancreatic cancers, juvenile diabetes, and neuroscience....
FDA Approves Nivolumab for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
On November 10, 2016, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. Approval was based on data from an...
Advanced Practitioners Convene at Fourth Annual JADPRO Live at APSHO
Launched in 2012 by Harborside Press, publisher of the Journal of the Advanced Practitioner in Oncology (JADPRO) and The ASCO Post, this year’s JADPRO Live at APSHO conference topped previous attendance records with nearly 1,100 attendees. APSHO, the Advanced Practitioner Society in Hematology and...
American Society of Hematology Honors David Grimwade, PhD, Posthumously With the 2016 Exemplary Service Award
The American Society of Hematology (ASH) will recognize the late David Grimwade, PhD, formerly of King’s College London and Guy’s and St. Thomas’ NHS Foundation Trust with the 2016 Exemplary Service Award for his exceptional years of service and dedication to the Society’s global programs that...
ASH Honors J. Evan Sadler, MD, PhD, and Ayalew Tefferi, MD, With the 2016 Henry M. Stratton Medal
The American Society of Hematology (ASH) will recognize J. Evan Sadler, MD, PhD, of Washington University School of Medicine in St. Louis, and Ayalew Tefferi, MD, of Mayo Clinic College of Medicine, with the 2016 Henry M. Stratton Medal for their seminal contributions in the areas of basic and...
ASH Reports Highest-Scoring Abstracts by Early-Career Researchers for Annual Meeting
The American Society of Hematology (ASH) recently announced that the following trainees received the highest-scoring abstracts in the categories of undergraduate student, medical student, graduate student, resident physician, and postdoctoral fellow for the 58th ASH Annual Meeting, December...
Drainage of Massive Ascites: Patient of Nicholas Senn, MD
Prior to the 20th century, there were very few specific therapies for disease. Many diseases, especially cancers and infections, resulted in accumulations of fluid or pus in body cavities. Physicians had to become masters of the trocar, needle, and catheter. They learned to artfully remove fluid...
Expect and Encourage Questions About Breast Reconstruction
An article in The New York Times about women who had chosen not to have reconstruction following breast cancer surgery might prompt questions from newly diagnosed patients considering their options.1 Deanna J. Attai, MD, FACS, told The ASCO Post that whenever an article on breast cancer appears in...
Helping Patients With Breast Cancer Decide Whether to Have Reconstruction
A “nascent movement to ‘go flat’” is how an article in The New York Times characterized the decisions by some women to opt out of reconstruction following surgery for breast cancer.1 The article examined the reasons several patients made that decision, which included avoiding multiple surgeries and ...
Elisabeth Heath, MD, FACP, Honored With 2016 Michigan Cancer Consortium Champion Award
Elisabeth Heath, MD, FACP, Leader of the Genitourinary Oncology Multidisciplinary Team and the Patricia C. and E. Jan Hartmann Endowed Chair for Prostate Cancer Research at the Barbara Ann Karmanos Cancer Institute, was recently honored with the Michigan Cancer Consortium’s inaugural Champion...
Dave, Dave, Dave
It was 1983, and I was in my third year as an attending physician at a major East Coast university medical center and just 5 years out of fellowship. As was common at the time, I saw and treated all malignancies except leukemia and gynecologic cancers. In the middle of a typically busy day at the ...
FDA Approves Daratumumab in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Multiple Myeloma
On November 21, 2016, the U.S. Food and Drug Administration (FDA) approved daratumumab (Darzalex) in combination with lenalidomide (Revlimid) and dexamethasone, or bortezomib (Velcade) and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior...
Center for Leukemia and Lymphoma Research at UNMC Renamed Dr. James O. Armitage Center for Leukemia and Lymphoma Research
The University of Nebraska Board of Regents voted to rename an area of the University of Nebraska Medical Center (UNMC) in honor of a longtime professor who has made extraordinary contributions to the institution. The Center for Leukemia and Lymphoma Research, established in 2003, was renamed by...
Safety Profile of Nivolumab Monotherapy in Advanced Melanoma
As reported in the Journal of Clinical Oncology, Weber et al performed a pooled analysis of the safety profile of nivolumab (Opdivo) monotherapy in advanced melanoma, including a focus on potential immune-related (select) adverse events. The analysis pooled safety data from 576 patients receiving...
Factors Predictive of Outcomes With Dabrafenib/Trametinib in Metastatic BRAF-Mutant Melanoma
Long et al identified factors predictive of progression-free and overall survival with combined dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with BRAF V600E–mutant or BRAF V600K–mutant metastatic melanoma, according to a pooled individual data analysis reported in The...
Pooled Analysis of Outcome With Nivolumab Alone or With Ipilimumab in Advanced Mucosal or Cutaneous Melanoma
A pooled analysis of outcomes in patients receiving nivolumab (Opdivo) or nivolumab plus ipilimumab (Yervoy) for advanced mucosal or cutaneous melanoma in clinical trials was reported by D’Angelo et al in the Journal of Clinical Oncology. The pooled analysis involved 889 patients who...
CAP/ASCP/ASCO Guideline on HER2 Testing and Clinical Decision-Making in Gastroesophageal Adenocarcinoma
As reported by Angela N. Bartley, MD, of St Joseph Mercy Hospital, Ann Arbor, and colleagues in the Journal of Clinical Oncology, the College of American Pathologists (CAP), the American Society for Clinical Pathology (ASCP), and ASCO have released a guideline on HER2 testing and clinical...
Bridge Medicines Launched to Advance Promising Early Technologies in Major Academic Institutions
Memorial Sloan Kettering Cancer Center, Rockefeller University, and Weill Cornell Medicine have announced that they have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd and health-care investment firms Bay City Capital ...
Michael O’Connell, MD, Receives the 2016 ACCC Clinical Research Award
Michael O’Connell, MD, received the Association of Community Cancer Centers (ACCC) 2016 Clinical Research Award in recognition of the significant and positive impact of his research on the oncology patient, family, and the community. ACCC President Jennie R. Crews, MD, MMM, FACP, accepted the...
Shirley A. Johnson, RN, MS, MBA, Joins Roswell Park Cancer Institute
Shirley A. Johnson, RN, MS, MBA, has been appointed as Roswell Park Cancer Institute’s Senior Vice President of Nursing and Patient Care Services and Chief Nursing Officer. Ms. Johnson officially joined the Roswell Park staff on October 31, 2016, bringing with her nearly 25 years of experience in...
Zhu Chen, MD, PhD, and Hugues de Thé, MD, PhD, to Present 2016 ASH Ernest Beutler Lecture
The American Society of Hematology (ASH) will honor Zhu Chen, MD, PhD, of Shanghai Institute of Hematology, and Hugues de Thé, MD, PhD, of Collège de France, with the 2016 Ernest Beutler Lecture and Prize for their significant research advances in the area of acute promyelocytic leukemia (APL)....
Dana-Farber Cancer Institute, Lifespan Partner to Advance Cancer Treatment and Expand Research
Dana-Farber Cancer Institute and Lifespan—Rhode Island’s first health system—leadership have signed a memorandum of understanding to form a partnership that will advance cancer treatment and expand research. The details will be finalized early next year. “Over the past 6 months, our staff members...
The Future of Health Care in America: Which Corridor?
It was mid-morning, and I was walking along one of the long corridors in our hospital, attending to clinical duties. From a distance, I noticed this elderly couple walking in the opposite direction. As we got closer, it became obvious that the elderly gentleman appeared winded and was looking...
Sleep Disruption in Cancer Survivors: Yoga Offers a Low-Risk Intervention With High Potential for Benefit
Impaired sleep quality is a concerning problem for many patients with cancer, and pharmacologic treatments come with many negative effects. Several small studies indicate that yoga improves persistent fatigue, sleep disturbance, anxiety, and quality of life, in addition to reducing the need for ...
How When Breath Becomes Air Is Helping the Public—and Physicians—Confront Their Mortality
It should not come as a surprise to anyone who has read Dr. Paul Kalanithi’s brilliant—and unforgettable—memoir, When Breath Becomes Air (Random House, 2016), that nearly a year after publication, it remains on The New York Times best-seller list, its popularity only increasing with time. Written...
Study Finds Cabozantinib of Clinical Benefit vs Sunitinib in Advanced Renal Cell Carcinoma
A randomized phase II clinical trial evaluating cabozantinib (Cabometyx) compared with standard-of-care sunitinib (Sutent) as first-line therapy for patients with advanced renal cell carcinoma has found that cabozantinib reduced the rate of disease progression or death by 34% compared with...
Making Peace With Cancer
Next to me sounds the buzzing of my Lympha Press machine, which substitutes for the constant visits of the physiotherapist who performs the lymph drainage. This gives me more freedom, and we have more privacy at home. I can use the machine whenever I need it, and my 5-year-old daughter, Christina, ...
Susan J. Mandel, MD, MPH, Named President-Elect of the Endocrine Society
Susan J. Mandel, MD, MPH, Director of Clinical Endocrinology and Diabetes for the University of Pennsylvania Health System, and Professor in the Division of Diabetes, Endocrinology, and Metabolism in Penn’s Perelman School of Medicine, has been elected President-Elect of the Endocrine Society. Dr. ...
Anne Gross, PhD, RN, NEA-BC, FAAN, Named Senior Vice President of Patient Care Services and Chief Nursing Officer at Dana-Farber
Anne Gross, PhD, RN, NEA-BC, FAAN, has been named Senior Vice President for Patient Care Services and Chief Nursing Officer at Dana-Farber Cancer Institute, effective December 1, 2016. Dr. Gross joined Dana-Farber in 2002 after 12 years at Cambridge Health Alliance as the nursing leader in...
A Lung Cancer Specialist Talks About Value in Cancer Care
Over the past few years, the term value-based cancer care has become integrated into the vernacular of the oncology community. Value is a subjective term, which is defined largely by its clinical setting. However, value in cancer care is evaluated by the multiple stakeholders involved in the...
Cary A. Presant, MD, FACP, FASCO, Receives ACCC David King Community Clinical Scientist Award
The Association of Community Cancer Centers (ACCC) honored Cary A. Presant, MD, FACP, FASCO, with the prestigious David King Community Clinical Scientist Award, for his demonstrated leadership in the development, participation, and evaluation of clinical studies for cancer patients. Throughout his ...
AMA Adopts Ethical Guidance on Team-Based Health Care
Team-based health-care models are emerging as preferred methods for providing coordinated, cost-effective and high-quality health care for patients. Earlier this month, the American Medical Association (AMA) announced its adoption of ethical guidance for physicians as leader-members of care ...
How Video Support Tools Help Patients Make Informed Decisions About End-of-Life Care
A relatively recent study by Areej El-Jawahri, MD, and her colleagues is showing how the use of visual media can empower patients with advanced cancer, as well as other life-threatening illnesses, to make more informed decisions about their end-of-life care.1 The aim of Dr. El-Jawahri’s study was ...
Understanding Biosimilars and Their Impending Role in Oncology Care
Biosimilars are among the newest threads in the fabric of cancer treatment in the United States, and they are spawning numerous questions for oncologists and patients with cancer. Many of these questions were taken up by participants in a recent Washington forum on “The Future of the U.S....
Charles G. Drake, MD, PhD, Joins NewYork-Presbyterian/Columbia University Medical Center
Charles G. Drake, MD, PhD, has joined NewYork-Presbyterian/Columbia University Medical Center as Director of Genitourinary Oncology and Associate Director for Clinical Research at the Herbert Irving Comprehensive Cancer Center. Dr. Drake will also serve as Co-Director of Columbia’s Cancer...
Adjuvant Sunitinib for Renal Cell Carcinoma: Not Ready for Prime Time
In renal cell carcinoma and other cancer types, a consistent paradigm in drug development exists: Observe efficacy of a drug in the metastatic setting and move quickly to explore the agent in the adjuvant setting. In the cytokine era, there were multiple efforts to characterize whether adjuvant...
Adjuvant Sunitinib Improves Disease-Free Survival in High-Risk Renal Cell Carcinoma After Nephrectomy
In the phase III S-TRAC trial reported at the recent European Society for Medical Oncology meeting and in The New England Journal of Medicine by Alain Ravaud, MD, PhD, of Bordeaux University Hospital, and colleagues, adjuvant sunitinib (Sutent) significantly prolonged disease-free survival vs...
Pembrolizumab in First-Line Treatment of Metastatic Non–Small Cell Lung Cancer
On October 24, 2016, pembrolizumab (Keytruda) was approved for use in patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have high programmed cell death ligand 1 (PD-L1) expression (tumor proportion score ≥ 50%) as determined by a U.S. Food and Drug Administration...
At ESMO 2016, Many Phase III Trials Fail to Meet Primary Endpoints
The 2016 European Society for Medical Oncology (ESMO) Congress revealed many important positive findings from key trials in a number of tumor types, but many highly anticipated phase III trials in advanced disease failed to meet their primary endpoints. The ASCO Post has summarized several of these ...
Study Finds EXITS Gene Mutations May Contribute to Cancer Sex Bias
According to Surveillance, Epidemiology, and end Results (SEER) data from 2008 to 2012, American males have an excess risk of 20.4% of developing any cancer compared with females, and there is a ≥ 2:1 male predominance for some individual cancers. This excess risk results in approximately...
Expert Point of View: Laurence Albiges, MD, PhD
Formal discussant Laurence Albiges, MD, PhD, of Institut Gustave Roussy, Villejuif, France, tried to put the results of KEYNOTE-052 and CheckMate 275 into perspective. “Anti–PD-1 (programmed cell death protein 1) and anti–PD-L1 (programmed cell death ligand 1) agents represent a revolution in the...
